Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory T(11;14) Multiple Myeloma

This study is testing a combination of two drugs — Belantamab Mafodotin (an antibody that targets cancer cells) and Venetoclax (a drug that promotes cancer cell death) — in people with a specific type of multiple myeloma (a blood cancer) that has returned or stopped responding to previous treatments, and that has a specific genetic change called t(11;14). **You may be eligible if...** - You are 18 or older - You have been diagnosed with multiple myeloma that has returned or is not responding to treatment (relapsed/refractory) - Your myeloma has a specific genetic marker called translocation t(11;14), confirmed by genetic testing - You have received at least one prior line of treatment, including a proteasome inhibitor and an immunomodulatory drug - Your disease is still measurable in the blood or urine **You may NOT be eligible if...** - You have serious eye conditions that cannot be managed - You have uncontrolled infections or serious organ problems - You are pregnant or breastfeeding - You have previously been treated with Belantamab Mafodotin or Venetoclax Talk to your doctor to see if this trial is right for you.